Shang Hai Zheng Quan Bao·2025-08-28 19:36Core Viewpoint - Fosun Pharma has demonstrated strong financial performance in the first half of the year, with a net profit of 1.702 billion yuan, representing a year-on-year increase of 38.96% [2][3] Financial Performance - In the first half of the year, Fosun Pharma achieved operating revenue of 19.514 billion yuan, with innovative drug revenue exceeding 4.3 billion yuan, a year-on-year growth of 14.26% [2][3] Innovation Strategy - Innovation remains the core engine for Fosun Pharma's growth, with a focus on diverse R&D models including self-development, collaboration, licensing, and investment [3][4] - The company has made significant progress in its pipeline, with 4 innovative drugs and 57 generic drugs approved during the reporting period, and nearly 20 innovative drug clinical trials approved [4] Strategic Direction - The company continues to adhere to its "4IN" strategy, focusing on Innovation, Internationalization, Intelligentization, and Integration [4][5] - The emphasis on innovation is expected to accelerate in terms of speed and quality, as well as global outreach and AI integration [4] International Expansion - Fosun Pharma aims to become a global Big Pharma, with overseas revenue reaching 5.478 billion yuan, accounting for 28.07% of total revenue [5][6] - The company is expanding its international market presence through partnerships and local registrations, particularly in emerging markets like the Middle East and Southeast Asia [6][7] Business Development Strategy - The company maintains a balanced approach between license-in and license-out strategies to enhance its product pipeline and support its global expansion [7] - Business development is seen as a crucial pathway for Fosun Pharma to enhance its global footprint and capabilities [7]